Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291.

Clostridium difficile is an anaerobic, gram-positive, spore-forming enteric pathogen that is associated with increasing morbidity and mortality and consequently poses an urgent threat to public health. Recurrence of a C. difficile infection (CDI) after successful treatment with antibiotics is high, occurring in 20-30% of patients, thus necessitating the discovery of novel therapeutics against this pathogen. Current animal models of CDI result in high mortality rates and thus do not approximate the chronic, insidious disease manifestations seen in humans with CDI. To evaluate therapeutics against C. difficile, a mouse model approximating human disease utilizing a clinically-relevant strain is needed. This protocol outlines the cefoperazone mouse model of CDI using a clinically-relevant and genetically-tractable strain, R20291. Techniques for clinical disease monitoring, C. difficile bacterial enumeration, toxin cytotoxicity, and histopathological changes throughout CDI in a mouse model are detailed in the protocol. Compared to other mouse models of CDI, this model is not uniformly lethal at the dose administered, allowing for the observation of a prolonged clinical course of infection concordant with the human disease. Therefore, this cefoperazone mouse model of CDI proves a valuable experimental platform to assess the effects of novel therapeutics on the amelioration of clinical disease and on the restoration of colonization resistance against C. difficile.

[1]  N. Minton,et al.  Improving the reproducibility of the NAP1/B1/027 epidemic strain R20291 in the hamster model of infection , 2016, Anaerobe.

[2]  Ed J. Kuijper,et al.  Clostridium difficile infection , 2016, Nature Reviews Disease Primers.

[3]  M. Wilcox,et al.  Clostridium difficile infection: epidemiology, diagnosis and understanding transmission , 2016, Nature Reviews Gastroenterology &Hepatology.

[4]  D. Gerding,et al.  Breakthroughs in the treatment and prevention of Clostridium difficile infection , 2016, Nature Reviews Gastroenterology &Hepatology.

[5]  V. Young,et al.  Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine , 2016, mSphere.

[6]  T. R. Licht,et al.  A catalog of the mouse gut metagenome , 2015, Nature Biotechnology.

[7]  D. Gerding,et al.  The epidemiology of Clostridium difficile infection inside and outside health care institutions. , 2015, Infectious disease clinics of North America.

[8]  J. Meek,et al.  Burden of Clostridium difficile infection in the United States. , 2015, The New England journal of medicine.

[9]  Casey M. Theriot,et al.  Dynamics and Establishment of Clostridium difficile Infection in the Murine Gastrointestinal Tract , 2014, Infection and Immunity.

[10]  V. Young,et al.  Persistence and Toxin Production by Clostridium difficile within Human Intestinal Organoids Result in Disruption of Epithelial Paracellular Barrier Function , 2014, Infection and Immunity.

[11]  S. Solomon,et al.  Antibiotic resistance threats in the United States: stepping back from the brink. , 2014, American family physician.

[12]  Bo Li,et al.  Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection , 2014, Nature Communications.

[13]  N. Minton,et al.  University of Birmingham Importance of Toxin A, Toxin B, and CDT in virulence of an epidemic Clostridium difficile strain , 2013 .

[14]  V. Young,et al.  Murine models to study Clostridium difficile infection and transmission. , 2013, Anaerobe.

[15]  Adrianne N. Edwards,et al.  Culturing and maintaining Clostridium difficile in an anaerobic environment. , 2013, Journal of visualized experiments : JoVE.

[16]  M. Pirmohamed,et al.  Emergence and global spread of epidemic healthcare-associated Clostridium difficile , 2012, Nature Genetics.

[17]  Margaret A. Olsen,et al.  Burden of Clostridium difficile on the Healthcare System , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Wilcox,et al.  Models for the study of Clostridium difficile infection , 2012, Gut microbes.

[19]  P. Treuting,et al.  Comparative Anatomy and Histology , 2012 .

[20]  B. Wren,et al.  Emergence of new PCR ribotypes from the hypervirulent Clostridium difficile 027 lineage. , 2012, Journal of medical microbiology.

[21]  D. Aronoff,et al.  Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains , 2011, Gut microbes.

[22]  Patrick D Schloss,et al.  The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection , 2011, Gut microbes.

[23]  S. Sattar,et al.  Clospore: a liquid medium for producing high titers of semi-purified spores of Clostridium difficile. , 2011, Journal of AOAC International.

[24]  Pamela Sears,et al.  Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.

[25]  M. Quail,et al.  Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium , 2009, Genome Biology.

[26]  D. Gerding,et al.  Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. , 2009, Gastroenterology.

[27]  Joseph A. Sorg,et al.  Laboratory Maintenance of Clostridium difficile , 2009, Current protocols in microbiology.

[28]  Jeffrey D Goldsmith,et al.  A mouse model of Clostridium difficile-associated disease. , 2008, Gastroenterology.

[29]  A. Azad,et al.  Growth and Maintenance of Vero Cell Lines , 2008, Current protocols in microbiology.

[30]  C. Kelly,et al.  Clostridium difficile--more difficult than ever. , 2008, The New England journal of medicine.

[31]  Carlene A. Muto,et al.  Antimicrobial-associated risk factors for Clostridium difficile infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  C. Kelly,et al.  Current Concepts Clostridium difficile — More Difficult Than Ever , 2008 .

[33]  D. Citron,et al.  Selective and differential medium for isolation of Clostridium difficile , 1979, Journal of clinical microbiology.

[34]  J. Bartlett,et al.  Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. , 1977, The Journal of infectious diseases.

[35]  J. Bartlett,et al.  Clindamycin-associated colitis in hamsters: protection with vancomycin. , 1977, Gastroenterology.